{"id":454044,"date":"2025-05-14T00:00:00","date_gmt":"2025-05-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0027-2025-biopharma-eosinophilic-esophagitis-unmet-need-unmet-need-eosinophilic-esophagitis-us-eu\/"},"modified":"2026-03-31T10:26:16","modified_gmt":"2026-03-31T10:26:16","slug":"unneim0027-2025-biopharma-eosinophilic-esophagitis-unmet-need-unmet-need-eosinophilic-esophagitis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0027-2025-biopharma-eosinophilic-esophagitis-unmet-need-unmet-need-eosinophilic-esophagitis-us-eu\/","title":{"rendered":"Eosinophilic Esophagitis &#8211; Unmet Need &#8211; Unmet Need &#8211; Eosinophilic Esophagitis (US\/EU)"},"content":{"rendered":"<p>Standard treatments for eosinophilic esophagitis (<abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr>) typically include proton pump inhibitors (<abbr data-abbreviation-entity=\"7476\" title=\"proton pump inhibitor\">PPI<\/abbr>s) and topical steroids. Although these therapies can alleviate <abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr> symptoms, their remission rates vary. Recently, new therapies have been introduced for the treatment of <abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr>, offering hope to patients. These agents include Takeda\u2019s Eohilia (budesonide oral suspension), which received <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> approval in 2024, and Sanofi \/ Regeneron\u2019s Dupixent (dupilumab), which received <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> approval in 2022 and <abbr data-abbreviation-entity=\"5851\" title=\"European Commission\">EC<\/abbr> approval in 2023. Additionally, the <abbr data-abbreviation-entity=\"5851\" title=\"European Commission\">EC<\/abbr> approved Dr. Falk\u2019s Jorveza (budesonide oral tablets) in 2018. The treatment landscape for <abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr> is evolving; several early- and late-phase agents (e.g., cendakimab, tezepelumab, APT-1011) offer targeted therapeutic approaches. Understanding prescriber perceptions of the available options and the drivers behind prescribers\u2019 clinical decision-making for the indication can help drug developers identify levers for new product positioning and differentiation.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do current therapies such as Dupixent, Eohilia, and Jorveza perform on key treatment drivers and goals for <abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr>?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>Where do surveyed gastroenterologists perceive the largest gaps in the treatment of <abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new <abbr data-abbreviation-entity=\"10304\" title=\"eosinophilic esophagitis\">EoE<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European gastroenterologist, fielded in March 2025<\/p>\n<p><strong>Key companies:<\/strong> Sanofi \/ Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Dr. Falk Pharma<\/p>\n<p><strong>Key drugs:<\/strong> Dupixent, Eohilia, Jorveza<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (<abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-454044","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/454044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/454044\/revisions"}],"predecessor-version":[{"id":454401,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/454044\/revisions\/454401"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=454044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}